Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.10.19
Views: 311

Dr Gail McIntyre - CSO, Aravive Biologics, Houston, Texas

Dr Gail McIntyre speaks to ecancer at ESMO 2019 in Barcelona about a phase Ib study using AVB500 in combination with paclitaxel or pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

She explains they have identified a biomarker that allows them to understand what dose of AVB500 will give the desired pharmacodynamic response.

Dr McIntyre reports that AVB500 was found to be safe and tolerable in the small cohort of patients, and adds that the next steps are to increase doses to reach a level they have identified as being associated with response.



· ESMO 2019

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation